Article Details
Retrieved on: 2021-02-15 19:41:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
In addition to CAR-T cell therapies, bispecific antibodies have also proven to show potential as alternative options in the relapsed/refractory setting. ... an anti-CD19 monoclonal antibody, with lenalidomide, an immunomodulator.
Article found on: www.onclive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here